U.S. FDA Opens New Safety Review of RSV Treatments for Infants

The U.S. Food and Drug Administration has launched a fresh safety scrutiny of newly approved RSV therapies for infants, signaling heightened regulatory caution as real-world usage expands. The review focuses on post-marketing safety signals emerging after the fast rollout of long-acting RSV antibodies and vaccines, which were initially approved to protect high-risk newborns and young infants from severe respiratory infection. While regulators emphasized that no immediate safety conclusions have been reached, the reassessment reflects growing vigilance as RSV products transition from controlled trials to nationwide pediatric use. The move places manufacturers under renewed pressure to strengthen pharmacovigilance as RSV prevention becomes a core pillar of pediatric infectious-disease strategy.